Eyenovia, Inc. (EYEN)

NASDAQ: EYEN · IEX Real-Time Price · USD
2.210
+0.230 (11.62%)
Feb 27, 2024, 11:37 AM EST - Market open
11.62%
Market Cap 87.36M
Revenue (ttm) 1,198
Net Income (ttm) -25.42M
Shares Out 44.12M
EPS (ttm) -0.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,312,055
Open 2.050
Previous Close 1.980
Day's Range 2.050 - 2.319
52-Week Range 1.050 - 5.850
Beta 1.74
Analysts Strong Buy
Price Target 10.00 (+352.49%)
Earnings Date Mar 28, 2024

About EYEN

Eyenovia, Inc., a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development pr... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 25, 2018
Employees 41
Stock Exchange NASDAQ
Ticker Symbol EYEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for EYEN stock is "Strong Buy." The 12-month stock price forecast is $10.0, which is an increase of 352.49% from the latest price.

Price Target
$10.0
(352.49% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility

Redwood City, California to complement Eyenovia's facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi

14 days ago - GlobeNewsWire

Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada

MicroPine, currently in late phase III for pediatric progressive myopia, to complement Eyenovia's commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007

6 weeks ago - GlobeNewsWire

Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update

Acquired U.S. commercial rights to APP13007, currently under FDA review for post-surgical ocular pain and inflammation, from Formosa Pharmaceuticals

3 months ago - GlobeNewsWire

Eyenovia to Report Third Quarter 2023 Results on Monday, November 13

Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT

4 months ago - GlobeNewsWire

Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for r...

4 months ago - GlobeNewsWire

Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO's 51st Annual Continuing Education (ACE) Program

Course to provide ophthalmic technicians with background on the Optejet dispensing technology and training on the use of Mydcombi™ for mydriasis

4 months ago - GlobeNewsWire

Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®

In rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions

5 months ago - GlobeNewsWire

Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of AP13007 for r...

5 months ago - GlobeNewsWire

Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for m...

6 months ago - GlobeNewsWire

Eyenovia Announces $12 Million Registered Direct Offering

NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for my...

6 months ago - GlobeNewsWire

Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals

APP13007, if approved, may have an advantageous profile in dosing frequency and side effects while reducing the inflammation and pain associated with ocular surgery

6 months ago - GlobeNewsWire

Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery

TAIPEI , Aug. 16, 2023 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into a licensing agreement with Eyenovia, Inc. ("Eyenovia...

6 months ago - PRNewsWire

Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update

Announced FDA approval of and first commercial sale of Mydcombi™, the only fixed dose combination of tropicamide and phenylephrine for mydriasis and the first FDA approved product to utilize the Optej...

7 months ago - GlobeNewsWire

Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/...

7 months ago - GlobeNewsWire

Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10

Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT

7 months ago - GlobeNewsWire

Eyenovia Announces First Commercial Sale of Mydcombi™

Represents the first FDA approved and commercially available fixed combination of tropicamide and phenylephrine for pupil dilation

7 months ago - GlobeNewsWire

Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes

NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company preparing for the launch of Mydcombi™ (tropicamide+phenylephrine ophthalmic ...

8 months ago - GlobeNewsWire

Glancy Prongay & Murray LLP Announces Investigation of Eyenovia, Inc. (EYEN)

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Eyenovia, Inc. (Nasdaq: EYEN) concerning the Company and its directors' and officers' possible violations ...

9 months ago - Business Wire

Eyenovia Expands Its US Manufacturing Capabilities

Eyenovia is stepping up the capabilities of its facilities and taking advantage of the thriving innovation culture and expertise in Reno, Nevada, and Redwood City, California NEW YORK, NY / ACCESSWIRE...

9 months ago - Accesswire

Eyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023

Presentation to highlight recent FDA approval of Mydcombi™ for mydriasis which leverages Eyenovia's novel Optejet dispensing device

9 months ago - GlobeNewsWire

Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update

Announced FDA approval of Mydcombi™, a fixed dose combination of tropicamide and phenylephrine for mydriasis, the first FDA approved product to utilize the Optejet ®

10 months ago - GlobeNewsWire

Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company's Proprietary Optejet® Device Platform

Represents the first FDA approved fixed-combination of tropicamide and phenylephrine for mydriasis Provides critical validation of key technology that is core to Eyenovia's proprietary development pro...

10 months ago - GlobeNewsWire

Eyenovia to Report First Quarter 2023 Results on Thursday, May 11

Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT

10 months ago - GlobeNewsWire

Eyenovia Announces Poster Presentation at ARVO 2023

NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its o...

11 months ago - GlobeNewsWire

Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update

Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023

11 months ago - GlobeNewsWire